Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,514 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Small RNA sequence, Rt-qPCR; Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cancer, Cancer Survivors, Informal Caregivers, Psychological Distress
Interventions: Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C), NCI Brochure; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Multiple Myeloma
Interventions: melphalan, topotecan (TPT), Autologous Stem Cell Rescue; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: Midazolam, Cefiderocol; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: AZD2389, Itraconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Head and Neck Cancer
Interventions: IMC-A12 (cixutumumab), cetuximab (Erbitux ®); Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 14
States / cities: Orange, California • Miami, Florida • Orlando, Florida + 11 more

Conditions: Menstrual Migraine (MM) Headaches
Interventions: Frovatriptan, Usual Care; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 21
States / cities: Stratford, Connecticut • Clearwater, Florida • Jacksonville, Florida + 18 more

Conditions: Melasma
Interventions: Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
Interventions: Quantitative ultrasound (DeepUSFF); Device
Lead sponsor: Seoul National University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Diabetes Mellitus
Interventions: insulin glargine, insulin glulisine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Surgical Stress Response, Stress Physiological, Stress Physiology, Stress Psychological, Breathing Techniques, Breathing Exercises, Hypothalamic Pituitary Adrenal, Relaxation, Relaxation Therapy, Cortisol, Postoperative Pain, Postoperative Anxiety, Postoperative Depression, Quality of Recovery (QoR-15)
Interventions: A 5-minute Asynchronous Breathwork Intervention, A 5-minute Asynchronous Card Game Video; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 65 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Visual Acuity
Interventions: Investigational senofilcon A C3 Multifocal Lens, delefilcon A Multifocal Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 7
States / cities: Bakersfield, California • Mission Viejo, California • Jacksonville, Florida + 3 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Sleep, Physical Activity
Interventions: Go/No-Go Task, Delay discounting task, Mirror Tracing Persistence Task, Spatial Span, Stop Signal Task, Flanker task; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 8 Years to 12 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Tumors
Interventions: S-1, FT; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Brensocatib; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Post Operative Pain, Acute, Periodontitis
Interventions: Dexamethasone IV injection, Dexamethasone Capsule, Placebo IV administration, Placebo capsule; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: GW642444, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Cypress, California • Huntington Beach, California • Denver, Colorado + 2 more

Conditions: Asthma
Interventions: Flovent Diskus® 100 mcg, Flovent Diskus® 250 mcg, Flovent Diskus® 500 mcg, Advair Diskus® 100/50 mcg, Advair Diskus® 250/50 mcg; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 28
States / cities: Tucson, Arizona • Oakland, California • San Francisco, California + 16 more

Conditions: Hypertension
Interventions: Metformin, CIN-107; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: GW679769 (Casopitant) oral tablets, Rifampin oral capsules; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Asthma
Interventions: Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 6 Years to 11 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Green Tree, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions: NKTR-118, Ketoconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Symptom Management for Rural-Urban Cancer Survivors and Caregivers

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

A Study of the Cardiac Effects of Danicopan in Healthy Adults

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

Quantitative Ultrasound (RS85 and R20) for Liver Fat Quantification in MASLD Using MRI-PDFF as Reference

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Feasibility of Breathwork Intervention With Older Adults After Knee Surgery

Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Hyperopic Population

Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

Best African American Response to Asthma Drugs

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118